Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
184
resultados
Última actualización
21/06/2025 [08:13:00]
Resultados 125 a 150 de 184
Resumen de: EP4549938A1
Problem Provided are a new marker of disease activity useful for testing a diseased state of vasculitis or an exacerbation risk of COVID-19, and a means for testing a diseased state of vasculitis or an exacerbation risk of COVID-19 using the marker.Solution According to an aspect of the present invention, there are provided a method for testing a diseased state of vasculitis and a method for testing an exacerbation risk of COVID-19, the method including: detecting or quantifying, in a blood sample collected from a subject,(1) a No. 1 APOA2-like protein that causes an antigen-antibody reaction with a single chain variable region fragment consisting of an amino acid sequence set forth in SEQ ID NO: 1 and has a molecular weight of 23 to 25 kDa, and/or(2) a No. 2 APOA2-like protein that causes an antigen-antibody reaction with a single chain variable region fragment consisting of an amino acid sequence set forth in SEQ ID NO: 1 and has a molecular weight of 16 to 20 kDa.
Resumen de: AU2023301087A1
Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural and/or functional features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells, pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.
Resumen de: WO2024007013A2
Disclosed are antigen binding antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural and/or functional features. Also disclosed are polynucleotides and vectors encoding such polypeptide complexes; host cells, pharmaceutical compositions and kits containing such polypeptide complexes; and methods of using such polypeptide complexes.
Resumen de: EP4549452A1
Provided are a pharmaceutical composition for resisting infection with SARS-CoV-2 or a mutant thereof, and a combined drug thereof. To solve the problem of the lack of effective prevention and treatment drugs for infection with SARS-CoV-2 or a mutant virus thereof, provided are a recombinant protein vaccine and/or an adenovirus vaccine for preventing and/or treating an infection with SARS-CoV-2 or a mutant thereof, and in particular, provided are a nasal spray administration compound formulation containing active ingredients of two vaccines, i.e., a recombinant protein vaccine and an adenovirus vaccine, and a combination of the two vaccines for nasal spray administration, which can induce generation of strong antibody and cellular immune responses in vivo and block the binding of a protein S of SARS-CoV-2 to an ACE2 receptor of a host cell, thus enabling a host to resist coronavirus infection. Particularly, the present invention has good prevention and treatment effects on various mutant viruses.
Resumen de: MX2024000185A
There are provided improved amphiphilic comb polymers, comprising a hydrophilic backbone with regularly-spaced pendant hydrophobic moieties, having well-controlled molecular weights, structures, and end groups. The polymers self-assemble into core-corona nanoparticles in aqueous environments, which are capable of disrupting viral coat proteins, and which are capable of encapsulating antiviral drugs and prodrugs. Regularly-spaced targeting moieties optionally mediate the adherence of the nanoparticles to the viral coat. The compositions of the invention are useful as treatments for viral infection, including infections with SARS-CoV-2.
Resumen de: KR20250059620A
본 발명은 프라이머 쌍 및 프로브를 포함하는 신종 코로나바이러스 19(SARS-CoV-2) 검출용 조성물 및 이를 이용한 신종 코로나바이러스 19(SARS-CoV-2) 검출방법에 관한 것으로, 보다 상세하게는 재조합효소 중합효소 증폭(Recombinase Polymerase Amplification; RPA)방법을 이용한 SARS-CoV-2 검출용 조성물, 키트 및 이를 이용한 SARS-CoV-2 검출방법에 관한 것이다.
Resumen de: WO2025089473A1
The present invention provides: a peptide set for quantifying and analyzing antigen proteins of individual subtypes from a specimen containing antigen proteins of a plurality of SARS-CoV-2 subtypes; and a method for simultaneously and quantitatively analyzing antigen proteins of SARS-CoV-2 subtypes according to types thereof, using same. The peptide set comprises one or more peptides specific to individual SARS-CoV-2 subtypes, selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 3, and a peptide common to SARS-CoV-2 subtypes, selected from SEQ ID NO: 4 or SEQ ID NO: 5.
Resumen de: NZ790708A
The invention discloses a composition comprising not less than 20% w/w bisdemethoxycurcumin for regeneration of alveolar cells damaged in emphysematous conditions and for the therapeutic management of chronic obstructive pulmonary disease and acute respiratory distress syndrome. The composition further comprises 10-35% w/w demethoxycurcumin and 10-45% wVw curcumin. The composition is very suitable for treating COPD and ARDS due to viral infections, specifically COVID 19 and for improving lung lunction during prognosis.
Resumen de: NZ791847A
Use of a class of ketoamide-based compounds, in particular, use of the ketoamide-based compound as represented by general formula A as a 2019 novel coronavirus (2019-nCov) 3CL protease inhibitor and/or human cathepsin L inhibitor in preparation of a medicament for treating and/or preventing and relieving respiratory tract infection, pneumonia and other related diseases caused by 2019 novel coronavirus infection. The present invention also relates to use of pharmaceutical compositions of the class of compounds, pharmaceutical salts, enantiomeric forms, diastereoisomers and racemic compounds thereof in preparation of a medicament for treating and/or preventing and relieving respiratory tract infections and other related diseases caused by the 2019 novel coronavirus infection.
Resumen de: US2025134097A1
Provided herein are compositions and related methods related to a class of formulation that can be applied once a day and still provide antimicrobial and/or antiviral protection during this period, thus exhibiting persistent sanitization to the user. In some embodiments, a hand cream with antimicrobial and/or antiviral protection can prevent against COVID-19 spread or infection. In some embodiments, the formulation comprises one or more of the following: benzalkonium chloride, zinc oxide, tributyl phosphate, soybean oil, and/or Triton X-100, or an analog, derivative, salt, or pharmaceutical equivalent thereof, with the formulation containing a predominance of water to prevent a greasy feel to the user.
Resumen de: US2025136668A1
The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically binds to a spike protein of SARS-CoV-2. The present disclosure also relates to a pharmaceutical composition, a method for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.
Resumen de: US2025134989A1
The present invention relates to a novel vaccine composition for coronavirus infection-19 comprising a polymer-based mRNA carrier. Specifically, the present invention provides a vaccine composition comprising an mRNA carrier using a novel polymer capable of delivering a negatively charged genetic material such as mRNA, and the vaccine composition has excellent effects of enhanced in vivo immune activity such as high antibody formation ability and increased interferon-gamma production.
Resumen de: US2025134985A1
Provided herein, in some aspects, are methods for using the receptor-binidng domain (RBD) of the SARS-COV-2 S protein, including the the RBD-1, RBD-2, and/or RBD-3 regions, to identify therapeutics for the treatment of SARS-COV-2, developing a vaccine for the treatment or prevention of SARS-COV-2, and identifying a patient as being in need for a treatment for SARS-COV-2.
Resumen de: US2025134987A1
The current disclosure includes coronavirus vaccines that protect against pathogenic coronavirus species, as well as their variants. In certain embodiments, SARS-CoV-2 variant specific and multivalent coronavirus vaccines are described. The vaccines typically include a modified mRNA which encodes at least one coronavirus derived immunogen, such as a spike protein or a fragment thereof. The mRNA can be encapsulated into lipid nanoparticles or other carriers and formulated as pharmaceutical compositions which can be used to generate an immune response to coronavirus in a subject. The vaccines can be used to elicit potent B and T cell responses against SARS-CoV-2 variants and to confer protective immunity against SARS-CoV-2, as well as other pathogenic coronavirus species such as SARS-CoV and/or MERS-CoV.
Resumen de: US2025134945A1
Various embodiments provide a method of increasing immunity to a virus in a subject. The method can comprise administering to the subject one or more effective doses of an immune-enhancing natural-based composition; thereby stimulating increased expression one or more of IFN-γ, IL-1B, IL-6, IL-10, IL-12p40, IL-12p70, and TNF-α; inhibiting replication of the virus inside a cell of the subject, and preventing entry of virus into the cell. The method of increasing immunity can further comprise increasing immunity to an upper respiratory tract viral infection. The upper respiratory tract viral infection can be COVID-19. According to some aspects of the method of increasing immunity, the effective dose of the immune-enhancing natural-based composition comprises: 30-70 mgs of cyanidin-3-glucosides; 40-80 mgs of andrographolides; 75-125 mgs of ascorbic acid; 400-600 mgs of beta glucans; 300-500 mgs of polysaccharides; and 75-125 mgs of a blend of antioxidants.
Resumen de: US2025134944A1
The present invention provides a new tea fraction, which is made from the non-ethanol extract, and does not contain caffeine, epigallocatechin gallate (EGCG), gallic acid and catechin that are usually found in conventional tea extracts. The tea fraction has an efficacy in treating a lung fibrosis, particularly idiopathic pulmonary fibrosis (IPF), Covid-19 and long Covid.
Resumen de: US2025137007A1
Disclosed is an alternate method of prevention and treatment of diseases caused by viral pathogens of human being and animals including coronaviruses, influenza viruses, etc., by food supplementation or fortification of food with foodstuff derived from transgenic plants or parts thereof obtained from the presently disclosed transgenic plant seed. This method provides said transgenic plant seed, wherein the genome of said seed comprises an exogenous recombinant polynucleotide encoding a combination of polypeptides, which are carbohydrate binding proteins, particularly lectins that in combination as disclosed herein are combined in a manner to overcome potential toxicity caused by their transgenic expression and to lower the concentrations of each of the carbohydrate binding proteins when expressed as a part of the combination when compared to the individual transgenic expression of any of said carbohydrate binding proteins, and wherein said seed exhibit inhibition of viral replication and provide immunity against viral pathogens.
Resumen de: US2025138005A1
Diagnostic assay devices for detecting the presence of an analyte in a sample solution may comprise a microreactor configured to form a sample solution containing the analyte, flow the sample solution therethrough in a first direction to form an analyte-capture molecule complex, and transfer the sample solution to an absorbent strip pad configured to flow therethrough, in a second direction crossing the first direction, the sample solution including the analyte-capture molecule complex and indicate a presence of the analyte-capture molecule complex. The diagnostic devices may be used, for example, to identify the presence of SARS-Cov2, RSV, influenza A, influenza B or other pathogens in samples from patients.
Resumen de: US2025138011A1
Kits containing a multiplexed chemiluminescent detection system and microfluidics devices and methods for detecting the presence and/or concentration of anti-SARS-CoV-2 antibodies in a sample are disclosed. The kits, microfluidics devices, and methods utilize singlet oxygen-activatable chemiluminescent compounds in combination with two or more fluorescent molecules that emit light at different wavelengths. In certain non-limiting embodiments, the kits, microfluidics devices, and methods can distinguish between anti-SARS-CoV-2 antibodies generated in response to vaccination from anti-SARS-CoV-2 antibodies generated in response to infection.
Resumen de: US2025138004A1
An apparatus for detecting a biomarker comprises a droplet harvesting structure for converting breath vapor to a fluid droplet for forming a fluid sample and a testing system having a biomarker testing zone for receiving the fluid sample and detecting a biomarker. The droplet harvesting structure may include at least one of a hydrophobic field for receiving the breath vapor and forming the fluid droplet from the received breath vapor and hydrophilic channels for receiving the fluid droplet and channeling the fluid droplet towards the testing system. A fluid dam member may be provided disposed between the droplet harvesting structure and the biomarker testing zone.
Resumen de: AU2023372393A1
Monoclonal antibodies that specifically bind to and block the function of Fas ligand (FasL) are described. The FasL-specific antibodies can be used for the development of therapeutics for the treatment of diseases, disorders and conditions associated with the Fas/FasL signaling pathway, such as cancer, sepsis, ischemia-reperfusion injury, and coronavirus disease 2019 (COVID-19).
Resumen de: WO2025089473A1
The present invention provides: a peptide set for quantifying and analyzing antigen proteins of individual subtypes from a specimen containing antigen proteins of a plurality of SARS-CoV-2 subtypes; and a method for simultaneously and quantitatively analyzing antigen proteins of SARS-CoV-2 subtypes according to types thereof, using same. The peptide set comprises one or more peptides specific to individual SARS-CoV-2 subtypes, selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 3, and a peptide common to SARS-CoV-2 subtypes, selected from SEQ ID NO: 4 or SEQ ID NO: 5.
Resumen de: WO2025090048A1
The invention relates to an optimer-based electrochemical biosensor for use in the determination of SARS-CoV-2 S1 protein and Moxifloxacin as well as the method for its operation. The invention also includes an application of said method for the diagnosis of disease and the determination of drugs. In this context, SARS-CoV-2 S1 protein and Moxifloxacin were selected as target analytes and electrochemical analyses of these target analytes were performed using optimer-based procedure and electrochemical impedance spectroscopy technique.
Resumen de: WO2025090605A1
The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
Nº publicación: WO2025088482A1 01/05/2025
Solicitante:
PHARMANUTRA S P A [IT]
PHARMANUTRA S.P.A
Resumen de: WO2025088482A1
The present invention relates to a composition, preferably a nutraceutical composition, for use in a method of treatment of subjects over 50 suffering from chronic fatigue, particularly due to: arthritis/chronic arthritis; heart disease; post-operative convalescence; depression; diabetes; fibromyalgia; chronic rheumatic diseases; stroke; cerebral ischemia; respiratory failure; chronic respiratory disease; allergic diseases; overweight/obesity; drug use, wherein said subjects are not suffering from Long-Covid/fatigue post Covid-19 syndrome.
BOPI
Sede Electrónica
